09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Software; software and hardware for diagnosing, monitoring,
measuring, calculating, analysing and displaying airway
inflammation and respiratory status; software and hardware
for analysing, storing, organising, categorising, tracking,
displaying and retrieving data regarding airway inflammation
and respiratory status; software and hardware for analysing,
storing, organising, categorising, tracking, displaying and
retrieving data from medical devices. Medical devices; medical apparatus and instruments; medical
apparatus for sampling of gases in human organs and for
control of pulmonary functionality; medical devices for
controlling the exhalation of oxygen in breath; medical
devices being containers for the storage of exhaled breath
samples; medical devices, namely, respiratory filters and
nozzles for use in sampling exhalation; medical devices,
namely, containers for sampling and storing of gas tests.
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Computer hardware and recorded software sold as a unit for diagnosing, monitoring, measuring, calculating, analysing and displaying airway inflammation and respiratory status; Computer hardware and recorded software sold as a unit for analysing, storing, organising, categorising, tracking, displaying and retrieving data regarding airway inflammation and respiratory status; Computer hardware and recorded software sold as a unit for analysing, storing, organising, categorising, tracking, displaying and retrieving data from medical devices Medical apparatus for sampling of gases in human organs and for control of pulmonary functionality; medical devices for controlling the exhalation of oxygen in breath; medical devices being containers for the storage of exhaled breath samples; medical devices, namely, respiratory filters and nozzles for use in sampling exhalation for medical purposes; medical devices, namely, containers for sampling and storing of medical gas tests
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Software and hardware for diagnosing, monitoring, measuring,
calculating, analysing and displaying airway inflammation
and respiratory status; software and hardware for analysing,
storing, organising, categorising, tracking, displaying and
retrieving data regarding airway inflammation and
respiratory status; software and hardware for analysing,
storing, organising, categorising, tracking, displaying and
retrieving data from medical devices. Medical devices; medical apparatus and instruments; medical
apparatus for sampling of gases in human organs and for
control of pulmonary functionality; medical devices for
controlling the exhalation of oxygen in breath; medical
devices being containers for the storage of exhaled breath
samples; medical devices, namely, respiratory filters and
nozzles for use in sampling exhalation; medical devices,
namely, containers for sampling and storing of gas tests.
09 - Scientific and electric apparatus and instruments
10 - Medical apparatus and instruments
Goods & Services
Computer hardware and recorded software sold as a unit for diagnosing, monitoring, measuring, calculating, analysing and displaying airway inflammation and respiratory status; computer hardware and recorded software sold as a unit for analysing, storing, organising, categorising, tracking, displaying and retrieving data regarding airway inflammation and respiratory status; computer hardware and recorded software sold as a unit for analysing, storing, organising, categorising, tracking, displaying and retrieving data from medical devices Medical apparatus for sampling of gases in human organs and for control of pulmonary functionality; medical devices for controlling the exhalation of oxygen in breath; medical devices being containers for the storage of exhaled breath samples; medical devices, namely, respiratory filters and nozzles for use in sampling exhalation; medical devices, namely, containers for sampling and storing of medical gas tests
5.
JAPANESE POLLEN ALLERGEN PEPTIDES FOR PREVENTING OR TREATING ALLERGY
A polypeptide or a pharmaceutically acceptable salt thereof and pharmaceutical formulations of at least three polypeptidesor salts thereof are provided which may be used for preventing or treating allergy to Japanese Cedar and/or Japanese Cypress pollen.
The present invention relates to a method of forming a concentrated solution of first and second pharmacologically active ingredients which involves: providing a solid eutectic composition of the first and second pharmacologically active ingredients; providing a first solvent; and dissolving the eutectic composition in the first solvent; wherein the first and second pharmacologically active ingredients are independently selected from β2 agonists, muscarinic antagonists, anticholinergics, corticosteroids, methylxanthine compounds and salts, esters, polymorphs, hydrates or solvates thereof. A solution obtainable by this method is also described, along with an ampoule for a nebuliser and a pressurised metered dose inhaler comprising the solution. The solution is useful in the treatment of respiratory diseases.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A process for preparing crystalline particles of an active principal in the presence of ultrasonic irradiation that comprises contacting a solution of a solute in a solvent in a first flowing stream with an anti-solvent in a second flowing stream causing the mixing thereof, wherein the flow rate ratio of the anti-solvent: solvent is higher than 20:1, and collecting crystals that are generated.
B01J 19/10 - Processes employing the direct application of electric or wave energy, or particle radiationApparatus therefor employing sonic or ultrasonic vibrations
B01J 2/02 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
B01J 2/18 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic using a vibrating apparatus
B01J 19/18 - Stationary reactors having moving elements inside
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations and substances;
pharmaceutical and veterinary preparations and substances
for the testing, diagnosis and treatment of allergies,
autoimmune disease, transplant rejection or immunodeficiency
disorders; reagent kits for testing and diagnosing
allergies, autoimmune disease, transplant rejection or
immunodeficiency disorders; vaccines.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations and substances;
pharmaceutical and veterinary preparations and substances
for the testing, diagnosis and treatment of allergies,
autoimmune disease, transplant rejection or immunodeficiency
disorders; reagent kits for testing and diagnosing
allergies, autoimmune disease, transplant rejection or
immunodeficiency disorders; vaccines.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations and substances; pharmaceutical and veterinary preparations and substances for the testing, diagnosis and treatment of allergies, autoimmune disease, transplant rejection or immunodeficiency disorders; reagent kits for testing and diagnosing allergies, autoimmune disease, transplant rejection or immunodeficiency disorders; vaccines.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations and substances; pharmaceutical and veterinary preparations and substances for the testing, diagnosis and treatment of allergies, autoimmune disease, transplant rejection or immunodeficiency disorders; reagent kits for testing and diagnosing allergies, autoimmune disease, transplant rejection or immunodeficiency disorders; vaccines.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations and substances; pharmaceutical and veterinary preparations and substances for the testing, diagnosis and treatment of allergies, autoimmune disease, transplant rejection or immunodeficiency disorders; reagent kits for testing and diagnosing allergies, autoimmune disease, transplant rejection or immunodeficiency disorders; vaccines.
16.
PHARMACEUTICAL COMPOSITIONS COMPRISING MULTI-COMPONENT CRYSTALLINE PARTICLES SUITABLE FOR USE IN INHALATION THERAPY
Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy and for delivery by oral or nasal inhalation are provided, wherein said compositions additionally comprise particles of at least one additional active agent. Also provided are methods of preparation of the compositions and their use in medicine.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
Pharmaceutical Preparations Multi-component crystalline particles and compositions, methods for their preparation, their uses in inhalation therapy and inhaler devices containing said particles are provided, in particular particles comprising glycopyrrolate. The particles can be prepared substantially free of excipients and agents other than active agents or their precursors in the presence of ultrasonic irradiation in a process comprising contacting a solution in a first flowing stream with an anti-solvent in a re-circulating second flowing stream, causing the mixing thereof and collecting crystals that are generated.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Pharmaceutical preparations for testing, diagnosis and treatment of allergies, autoimmune disease, transplant rejection and immunodeficiency disorders; veterinary pharmaceutical preparations for testing, diagnosis and treatment of allergies, autoimmune disease, transplant rejection and immunodeficiency disorders; Vaccines for human and veterinary use; Surgical, medical and veterinary apparatus and instruments, namely, kits comprised of pharmaceutical preparations, reagents and chemicals for testing, diagnosing and treating allergies and other immunodeficiency disorders. (1) Pharmacological research services; Research and development in the pharmaceutical and biotechnology fields; Providing medical and scientific research information in the fields of pharmaceutical and clinical trials; Conducting clinical trials; information, advisory and consultancy services relating to the aforesaid.
19.
JAPANESE CEDAR PEPTIDE FOR PREVENTING OR TREATING ALLERGY
A polypeptide which may be used for preventing or treating allergy to Japanese Cedar and/or Japanese Cypress pollen, is up to 30 amino acids in length, and comprises (I) the amino acid sequence: DLKIKLRRTIEAEGIP(SEQ ID NO: 1; Cry26); or(II)a T cell epitope-containing variant sequence which is a said amino acid sequence (I) having up to seven amino acid modifications, each of which is independently a deletion, substitution or insertion.
Pharmaceutical formulations,which may be used for preventing or treating allergy to moulds of the Alternaria and/or Cladosporiumgenus, comprising a pharmaceutically acceptable carrier or diluent and a polypeptide or a pharmaceutically acceptable salt thereof selected from at least three of: (a)a polypeptide comprising the amino acid sequence of WSWKIGPAIATGNT(Alt28; SEQ ID NO: 101) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (b)a polypeptide comprising the amino acid sequence of KYRRVVRAGVKVAQTAR(Alt34A; SEQ ID NO: 107) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (c) a polypeptide comprising the amino acid sequence of KYAGVFVSTGTLGGG (SEQ ID NO: 112) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (d)a polypeptide comprising the amino acid sequence of AEVYQKLKALAKKTYGQ(Alt13A; SEQ ID NO: 83) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (e)a polypeptide comprising the amino acid sequence of SLGFNIKATNGGTLD(Alt01A; SEQ ID NO: 60)or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (f) a polypeptide comprising the amino acid sequence of SAKRMKVAFKLDIEK(Alt06; SEQ ID NO: 72) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (g)a polypeptide comprising the amino acid sequence of DITYVATATLPNYCR(SEQ ID NO: 111) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; and (h)a polypeptide comprising the amino acid sequence of GWGVMVSHRSGET(Alt14;SEQ ID NO: 84) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; wherein a T cell epitope-containing variant sequence of a said amino acid sequence is said amino acid sequence having up to seven amino acid modifications, each of which is independently a deletion, substitution or insertion, and each polypeptide is up to 30 amino acids in length.
Polypeptides which may be used for preventing or treating allergy to moulds of the Cladosporium and/or Alternaria genus, have up to 30 amino acids in length and comprise: (I) the amino acid sequence: (a) GGYKAAVRPTMLE (SEQ ID NO : 35; Cla35), (b) AE V YQKLK SLTKK (SEQ ID NO: 31; Clal6), (c) VAITYASRAQGAE (SEQ ID NO: 32; Cla25), (d) GHHFKERGTGSLVIT (SEQ ID NO: 33; Cla26), or (e) ANYTQTKTVSIRL (SEQ ID NO: 34; Cla29); or (II) a T cell epitope-containing variant sequence which is a said amino acid sequence (I) having up to six amino acid modifications, each of which is independently a deletion, substitution or insertion.
The present invention relates to a hydrochloride salt of a peptide consisting of the sequence of CPAVKRDVDLFLT (SEQ ID NO: 1) as well as its combinations with other peptides for immunosuppressive purposes.
The present invention relates to compositions comprising peptides for preventing or treating allergy to birch, and in particular to optimal combinations of peptides for preventing or treating said allergy.
This invention provides a pharmaceutical composition comprising a eutectic composition of two pharmacologically active ingredients for delivery to the lung by inhalation. This invention also provides a pharmaceutical composition comprising a eutectic composition of two pharmacologically active ingredients for the treatment of respiratory disease.
The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.
The present invention relates to compositions comprising peptides for preventing or treating allergy to birch, and in particular to optimal combinations of peptides for preventing or treating said allergy.
This invention provides a process for increasing the crystallinity of at least one solid material which is less than 100% crystalline, comprising contacting said solid material with solvent in which the solid material is insoluble or poorly soluble (a non-solvent); and applying ultrasound to the solid material when in contact with said non-solvent.
B32B 5/16 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by features of a layer formed of particles, e.g. chips, chopped fibres, powder
C30B 29/60 - Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape characterised by shape
A61K 9/00 - Medicinal preparations characterised by special physical form
The invention provides a process for increasing the crystallinity of at least one solid material which is less than 100 % crystalline, comprising applying ultrasound to the substantially dry solid material.
The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.
The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides.
The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.
A process for preparing an emulsion or a dispersion comprising crystalline particles of at least one active principal that comprises contacting a solution of at least one solute in a solvent or mixture of solvents in a first flowing stream with a non-solvent in a second flowing stream wherein the non-solvent and solvent are not miscible with each other, so as to form an emulsion or a dispersion. Super saturation is brought about by suitable means, and the emulsion or dispersion is subjected to ultrasonic irradiation to mediate crystal nucleation.
B01J 19/10 - Processes employing the direct application of electric or wave energy, or particle radiationApparatus therefor employing sonic or ultrasonic vibrations
B01J 2/06 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a liquid medium
A61K 9/00 - Medicinal preparations characterised by special physical form
B01J 2/18 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic using a vibrating apparatus
This invention provides an oscillating baffled reactor apparatus for preparing crystalline particles of at least one substance comprising: a reactor vessel; means for supplying a first flowing stream; means for oscillating fluid within the reactor vessel; a plurality of baffles; source of ultrasonic radiation; and means for collecting said particles.
B01J 19/00 - Chemical, physical or physico-chemical processes in generalTheir relevant apparatus
B01J 19/10 - Processes employing the direct application of electric or wave energy, or particle radiationApparatus therefor employing sonic or ultrasonic vibrations
B01J 19/18 - Stationary reactors having moving elements inside
The present invention relates to the use of a non-reducing carbohydrate or carbohydrate derivative and at least one agent which inhibits dimer formation in a freeze-dried composition comprising at least one peptide that contains a free cysteine residue, to provide a freeze-dried composition with improved long-term storage stability.
The present invention relates to compositions for preventing or treating allergy to ragweed by tolerisation. The compositions are based on combinations of peptide fragments derived from the major allergen in ragweed pollen, Amb a 1. The invention also relates to products, vectors and formulations which may be used to provide polypeptides of the invention in combination. The invention further relates to in vitro methods for determining whether T cells recognize a polypeptide of the invention, and for determining whether an individual has or is at risk of a condition characterized by allergic symptoms in response to a ragweed allergen.
A first or second polypeptide for use in a method of treating or preventing a disorder by tolerisation, wherein said method comprises administration of the first and second polypeptide; and wherein both first and second polypeptides: i) are of 7 to 30 amino acids in length; ii) comprise at least one MHC Class Il-binding T cell epitope; and iii) are a fragment of a protein allergen or a homologous variant of said fragment; wherein said first polypeptide induces the release of an amount of IL-10 that is greater than the amount of IL-10 released in response to the whole protein allergen from which the first polypeptide derives; wherein said disorder is characterised by an inappropriate immune response to the protein allergen from which the second polypeptide derives.
A process for preparing crystalline particles of an active principal in the presence of ultrasonic irradiation that comprises contacting a solution of a solute in a solvent in a first flowing stream with an anti-solvent in a second flowing stream causing the mixing thereof, wherein the flow rate ratio of the anti-solvent: solvent is higher than 20:1, and collecting crystals that are generated.
B01J 19/10 - Processes employing the direct application of electric or wave energy, or particle radiationApparatus therefor employing sonic or ultrasonic vibrations
This invention provides a process for increasing the crystallinity of at least one solid material comprising a fluticasone compound which is less than 100% crystalline, comprising contacting said solid material with solvent in which the solid material is insoluble or poorly soluble (a non-solvent); and applying ultrasound to the solid material when in contact with said non-solvent.
B01D 1/18 - Evaporating by spraying to obtain dry solids
F26B 5/06 - Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
F26B 3/12 - Drying solid materials or objects by processes involving the application of heat by convection, i.e. heat being conveyed from a heat source to the materials or objects to be dried by a gas or vapour, e.g. air the gas or vapour carrying the materials or objects to be dried with it in the form of a spray
This invention provides a process for increasing the crystallinity of at least one solid material which is less than 100% crystalline, comprising contacting said solid material with solvent in which the solid material is insoluble or poorly soluble (a non-solvent); and applying ultrasound to the solid material when in contact with said non-solvent.
B01D 1/18 - Evaporating by spraying to obtain dry solids
F26B 5/06 - Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
F26B 3/12 - Drying solid materials or objects by processes involving the application of heat by convection, i.e. heat being conveyed from a heat source to the materials or objects to be dried by a gas or vapour, e.g. air the gas or vapour carrying the materials or objects to be dried with it in the form of a spray
The present invention relates to compositions comprising peptides for preventing or treating the development of inhibitors in patients with haemophilia, in particular certain peptides and / or peptide fragments derived from factor VIII.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Treating liquids, droplets of liquid, and particles with ultrasonic waves to modify their properties in the pharmaceutical industry and in the chemical industry; technical consultancy services in the field of ultrasonic treatment of liquids, droplets of liquid, and particles to modify their properties in the pharmaceutical industry and in the chemical industry.
C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 4/06 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof from fungi
C07K 4/10 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof from plants
C07K 4/12 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof from animalsPeptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof from humans
C07K 7/00 - Peptides having 5 to 20 amino acids in a fully defined sequenceDerivatives thereof
The present invention relates to compositions comprising peptides for preventing or treating allergy to house dust mites, and in particular to optimal combinations of peptides for preventing or treating said allergy.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present invention relates to soluble peptides comprising T cell epitopes and methods for engineering insoluble peptides comprising T cell epitopes to improve solubility.
A process for preparing an emulsion or a dispersion comprising crystalline particles of at least one active principal that comprises contacting a solution of at least one solute in a solvent or mixture of solvents in a first flowing stream with a non-solvent in a second flowing stream wherein the non-solvent and solvent are not miscible with each other, so as to form an emulsion or a dispersion. Super saturation is brought about by suitable means, and the emulsion or dispersion is subjected to ultrasonic irradiation to mediate crystal nucleation.
B01J 2/02 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
B01J 2/18 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic using a vibrating apparatus
The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides.
The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides.
The invention provides an in vitro method of determining whether an individual is at risk of, or undergoing, graft damage or rejection of immune origin and/or damage of immune origin to non-graft tissue using polypeptides derived from a major histocompatibility complex (MHC) class I human leukocyte antigen (HLA), such as HLA-A2, and derivatives or analogues thereof.
A process for preparing crystalline particles of an active principal in the presence of ultrasonic irradiation that comprises contacting a solution of a solute in a solvent in a first flowing stream with an anti-solvent in a second flowing stream causing the mixing thereof, wherein the flow rate ratio of the anti- solvent: solvent is higher than 20:1, and collecting crystals that are generated.
B01J 2/02 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
B01J 2/18 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic using a vibrating apparatus
A61K 9/00 - Medicinal preparations characterised by special physical form
52.
PROCESS FOR MAKING CRYSTALS VIA ULTRASONIC IRRADIATION OF A CLOSED LOOP
A process for preparing crystalline particles of an active principal in the presence of ultrasonic irradiation that comprises contacting a solution of a solute in a solvent in a first flowing stream with an anti-solvent in a second flowing stream causing the mixing thereof, wherein the flow rate ratio of the anti- solvent: solvent is higher than 20:1, and collecting crystals that are generated.
A61K 9/00 - Medicinal preparations characterised by special physical form
B01J 2/02 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
B01J 2/18 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic using a vibrating apparatus
The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides.
